Immunomodulating agents such as anti–programmed cell death protein 1 (PD-1) have recently gained a crucial role in the treatment of numerous human malignant tumors.1 Cemiplimab is a novel PD-1 blocker approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for curative surgery or radiation.2 During the last few years, other anti–PD-1 agents such as pembrolizumab and nivolumab have occasionally been used off-label to manage cases of advanced cSCC.3 We describe 1 patient with recessive dystrophic epidermolysis bullosa (RDEB) and multiple cSCCs who was successfully treated with pembrolizumab.

Piccerillo, A., El Hachem, M., De Vito, R., De Luca, E., Peris, K., Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa., <<JAMA DERMATOLOGY>>, 2020; 2020 (22 Apr): N/A-N/A. [doi:10.1001/jamadermatol.2020.0304] [http://hdl.handle.net/10807/152564]

Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

Piccerillo, A;El Hachem, M;Peris, K.
2020

Abstract

Immunomodulating agents such as anti–programmed cell death protein 1 (PD-1) have recently gained a crucial role in the treatment of numerous human malignant tumors.1 Cemiplimab is a novel PD-1 blocker approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for curative surgery or radiation.2 During the last few years, other anti–PD-1 agents such as pembrolizumab and nivolumab have occasionally been used off-label to manage cases of advanced cSCC.3 We describe 1 patient with recessive dystrophic epidermolysis bullosa (RDEB) and multiple cSCCs who was successfully treated with pembrolizumab.
Inglese
Piccerillo, A., El Hachem, M., De Vito, R., De Luca, E., Peris, K., Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa., <<JAMA DERMATOLOGY>>, 2020; 2020 (22 Apr): N/A-N/A. [doi:10.1001/jamadermatol.2020.0304] [http://hdl.handle.net/10807/152564]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/152564
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact